Overactive Bladder Research Articles

Use of the Oral Sialogogue “Oriza Tablet” in Reducing Drug-Induced Xerostomia in Patients with Overactive Bladder or Neurogenic Bladder: Randomized Clinical Study

Purpose Evaluate the clinical efficacy of “Oriza tablet” (OT) for patients with neurologic bladder or overactive bladder affected by xerostomia due to receiving antimuscarinic drugs. Material and methods This was a randomized clinical trial. Twenty-eight patients (median age = 64 years) with xerostomia were divided into two groups: OT (intervention group) and placebo (control) group. Both groups comprised 14 patients each. Objective We assessed severity using a questionnaire for the subjective evaluation of xerostomia. Objective evaluation was undertaken for the stimulated salivary flow rate (SSFR). Xerostomia evaluation took place before treatment (baseline) as well as 2 weeks and 4 weeks after treatment. Results The xerostomia score decreased significantly ( p < 0.05) in the OT group compared to the placebo group, with scores of 2.75 versus 4.4 at 2 weeks and 2.19 versus 4.13 at 4 weeks, respectively. The SSFR increased significantly ( p < 0.05) in the OT group compared to the placebo group, with SSFR of 2 versus 1.2 at 2 weeks and 1.85 versus 1.1 at 4 weeks, respectively. Throughout the trial, no patient discontinued taking antimuscarinic medications. There were no adverse effects noted. Conclusion Continuous daily use of OT for 4 weeks reduced xerostomia symptoms and increased saliva production in patients suffering from neurologic bladder or overactive bladder who received antimuscarinic medications. Clinical trial registration The study was registered with The Thai Clinical Trials Registry (TCTR). ID: TCTR20240715015.

169 - A closer look into overactive bladder syndrome: exploring the use of NESA microcurrents neuromodulation.

169 - A closer look into overactive bladder syndrome: exploring the use of NESA microcurrents neuromodulation.

168 - Dorsal Genital Nerve stimulation in patients with overactive bladder syndrome. A feasibility study with the novel UCon neurostimulator

168 - Dorsal Genital Nerve stimulation in patients with overactive bladder syndrome. A feasibility study with the novel UCon neurostimulator

Control of nerve-mediated and urothelial ATP release by a protein kinase G-dependent pathway in the mouse bladder

Aim:ATP signalling is involved in urinary bladder motor and sensory pathways, including stimulation-mediated release from parasympathetic varicosities to detrusor muscle and from urothelial cells when mechanically stressed. Both modalities are present in humans and other mammals but are especially prominent in overactive bladder syndromes. There is therefore an unmet need to understand how to regulate such release. This study tested the hypothesis that the nitric oxide (NO•)/ soluble guanylate cyclase (sGC)/ cyclic GMP/ protein kinase-G (PKG) pathway has a central role. Methods:In vitro nerve-mediated contractions and ATP/acetylcholine (ACh) release were measured from bladder wall strips, as was ATP release from urothelial cell suspensions subject to mechanical stresses. Enhanced spontaneous contractile activity was also measured in bladder wall preparations of spinal cord-injured mice. Interventions were designed to increase cellular cGMP levels (a cell-permeable cGMP analogue, a NO•donor, a phosphodiesterase inhibitor (PDEI), a sGC activator), or agents to reduce activity of pathway enzymes (sCG or PKG). Results:ATP-dependent contractions were reduced by the above interventions, as was ATP release; but ACh-dependent contractions and ACh release were unaffected. Spontaneous contractile activity was also reduced by the cGMP analogue and by a PDEI. ATP release from urothelial cell suspensions was also reduced by similar interventions. Conclusions:ATP release from efferent nerves and from urothelial cells were selectively reduced by upregulating the NO•/sGC/cGMP/PKG pathway. Translational aspects are discussed with respect to purinergic pathways and overactive bladder pathologies.

173 - Predictive factors for clean intermittent catheterization after intravesical onabotulinumtoxinA injections in women with overactive bladder syndrome: A Danish retrospective cohort study

173 - Predictive factors for clean intermittent catheterization after intravesical onabotulinumtoxinA injections in women with overactive bladder syndrome: A Danish retrospective cohort study

216 - Persistence of Vibegron treatment in elderly patients aged 80 years or over with overactive bladder: The impact of anticholinergic burden and polypharmacy

216 - Persistence of Vibegron treatment in elderly patients aged 80 years or over with overactive bladder: The impact of anticholinergic burden and polypharmacy

220 - Causes for Overactive Bladder Symptoms should be investigated in patients with age-related white matter hyperintensities - results from the One Step Towards OverActive Bladder Phenotyping (OSTOAP) Study

220 - Causes for Overactive Bladder Symptoms should be investigated in patients with age-related white matter hyperintensities - results from the One Step Towards OverActive Bladder Phenotyping (OSTOAP) Study

268 - A study on the association between equol and overactive bladder

268 - A study on the association between equol and overactive bladder

222 - Relationship between salt intake and overactive bladder

222 - Relationship between salt intake and overactive bladder

171 - Comparison of the Transcutaneous Posterior Tibial Nerve Stimulation and Solifenacin Treatments’ Effects in Women with Overactive Bladder

171 - Comparison of the Transcutaneous Posterior Tibial Nerve Stimulation and Solifenacin Treatments’ Effects in Women with Overactive Bladder

226 - A low Incidence of urinary tract cancers among patients with overactive bladder

226 - A low Incidence of urinary tract cancers among patients with overactive bladder

Babcock versus Scissor Tensioning for Retropubic Mid-Urethral Slings: Comparing Two Intra-Operative Techniques Through 5 Years of Follow-Up.

The objective was to determine if mid-urethral sling (MUS) tensioning with a Mayo Scissor as a sub-urethral spacer compared with a Babcock clamp holding a loop of tape under the urethra results in differences in patient-reported outcomes and rates of repeat surgery over a 5-year follow-up. Follow-up 5 years after a randomized clinical trial, utilizing primary data collection linked to administrative health data, was carried out to create a longitudinal cohort. The primary outcome was participant-reported bothersome SUI symptoms, as defined by the Urogenital Distress Inventory (UDI-6) questionnaire. Secondary outcomes included participant-reported bothersome overactive bladder (OAB) scores, median scores of three validated urinary symptom questionnaires, and rates of subsequent surgery determined through patient report and administrative data. Two hundred and sixty (81.8%) of the original study participants provided participant-reported data at 5 years. Administrative data linkage was completed for all of the original participants (n = 318). Demographic characteristics remained similar in the two groups at the 5-year follow-up mark. No differences existed in the primary outcome of reported bothersome SUI symptoms (30.8% Scissors vs 26.8% Babcock, p = 0.559), proportion of participants with bothersome OAB, the median scores of three validated bladder questionnaires, or in rates and cumulative incidence of recurrent MUS surgery or surgical revision of mesh-related complications. Both the Scissor and Babcock tensioning techniques provided comparable outcomes at 5 years post-MUS surgery. The information from this study allows surgeons to better decide which technique to adopt in their practice, providing confidence in longer-term cure and safety.

Real-World Use of Intradetrusor Botulinum Toxin Injections: A Population-Based Study from France.

In recent decades, intradetrusor injections of botulinum toxin A (BoNT-A) have been widely applied to treat incontinence in both idiopathic overactive bladder (iOAB) and neurogenic detrusor overactivity incontinence (NDOI). This analysis, based on the French National Hospital Discharge Database (PMSI), aims to describe real-world trends in intradetrusor BoNT-A use between 2014 and 2022. Among 32,864 patients who received at least one intradetrusor BoNT-A injection, 18,320 (55.7%) had conditions coded under iOAB, 13,376 (40.7%) under NDOI, and 1168 (3.6%) under other indications. The overall mean interval between two intradetrusor BoNT-A injections was 9.7 months, ranging from 8.7 months in patients with multiple sclerosis (MS) to 11.5 months in patients with cerebral pathologies. The median number of injections was two (quartile 1-quartile 3, 1-4) in patients with spina bifida, whereas it was five (2-10) in those with MS. Only 31% of patients with iOAB received more than two intradetrusor BoNT-A injections. Regardless of its indication, BoNT-A was well tolerated. Adverse events occurring during or requiring hospitalization included infections (3.8%), hematuria (0.53%), and bleeding episodes necessitating transfusions (0.11%), all recorded within the initial month following BoNT-A injection. Our analysis of the PMSI database highlights a broad spectrum of intradetrusor BoNT-A injection practices.

219 - Characterization of the Urethral Virome in Female Patients with Overactive Bladder Syndrome compared to Controls: a pilot study

219 - Characterization of the Urethral Virome in Female Patients with Overactive Bladder Syndrome compared to Controls: a pilot study

267 - Darifenacin versus Parasacral Transcutaneous Electrical Nerve Stimulation for Overactive Bladder Syndrome in Patients Infected With Human T-Cell Lymphotropic Virus 1 – Preliminary Results of a Randomized Clinical Trial

267 - Darifenacin versus Parasacral Transcutaneous Electrical Nerve Stimulation for Overactive Bladder Syndrome in Patients Infected With Human T-Cell Lymphotropic Virus 1 – Preliminary Results of a Randomized Clinical Trial

86 - Identification of brain regions responsible for overactive bladder associated with vesical adaptation response of diuresis

86 - Identification of brain regions responsible for overactive bladder associated with vesical adaptation response of diuresis

Activation mechanism and novel binding sites of the BKCa channel activator CTIBD.

The large-conductance calcium-activated potassium (BKCa) channel, which is crucial for urinary bladder smooth muscle relaxation, is a potential target for overactive bladder treatment. Our prior work unveiled CTIBD as a promising BKCa channel activator, altering V 1/2 and G max This study investigates CTIBD's activation mechanism, revealing its independence from the Ca2+ and membrane voltage sensing of the BKCa channel. Cryo-electron microscopy disclosed that two CTIBD molecules bind to hydrophobic regions on the extracellular side of the lipid bilayer. Key residues (W22, W203, and F266) are important for CTIBD binding, and their replacement with alanine reduces CTIBD-mediated channel activation. The triple-mutant (W22A/W203A/F266A) channel showed the smallest V 1/2 shift with a minimal impact on activation and deactivation kinetics by CTIBD. At the single-channel level, CTIBD treatment was much less effective at increasing P o in the triple mutant, mainly because of a drastically increased dissociation rate compared with the WT. These findings highlight CTIBD's mechanism, offering crucial insights for developing small-molecule treatments for BKCa-related pathophysiological conditions.

206 - Pelvic Floor Muscle Training Exercise Prescription Components Currently used for Overactive Bladder

206 - Pelvic Floor Muscle Training Exercise Prescription Components Currently used for Overactive Bladder

178 - Botuline Toxine A in Overactive Bladder Therapy: Variation in Practice Amongst 258 Survey Responders in Belgium and the Netherlands

178 - Botuline Toxine A in Overactive Bladder Therapy: Variation in Practice Amongst 258 Survey Responders in Belgium and the Netherlands

221 - Urinary Na/K ratio as a predictive tool in diagnosing overactive bladder

221 - Urinary Na/K ratio as a predictive tool in diagnosing overactive bladder